Testing tasquinimod or paquinimod has been suggested as a clinical strategy for patients with severe COVID‐19 since plasma calprotectin (S100A8/A9) level positively correlates with disease severity.[40, 41] In the current study, the presence of kidney S100A8/S100A9+ macrophage infiltration and the relevance of renal S100a8/a9 expression to the degree of renal tubular pathological injury, tubule cell apoptosis, and renal dysfunction were confirmed in human AKI with nephrotoxic or renal ischemic etiologies. This evidence concerns the gene IGKV1D-22 and COVID-19.